Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on April 29, 2020. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing requirements rather than financial performance.
Material Changes
- Reverse Stock Split: On April 14, 2020, the Company implemented a one-for-twenty reverse stock split of its outstanding common stock.
- Nasdaq Compliance: As of the close of business on April 28, 2020, the Company evidenced compliance with Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule") by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
- Resolution of Delinquency: The Company was previously granted an extension through June 12, 2020, to regain compliance. The notification on April 29, 2020, confirms full compliance, and the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies. The primary risk addressed was the potential delisting due to failure to meet the minimum bid price requirement, which has been resolved.
Investor Verification Checklist
- Verify the post-split share count and adjusted trading price on Nasdaq.
- Confirm the current status of the reverse stock split implementation in subsequent filings.
- Review the company's capital structure to understand the impact of the one-for-twenty split on existing holdings.